Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAJ.0b013e3181dd1aa5 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
12
cell carcinoma
12
treatment renal
8
improvement psoriasis
4
psoriasis sunitinib
4
sunitinib therapy
4
therapy renal
4
carcinoma sunitinib
4
sunitinib oral
4
oral tyrosine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!